



## Repair Therapeutics to Participate at the Goldman Sachs 44th Annual Global Healthcare Conference

June 8, 2023

CAMBRIDGE, Mass. & MONTREAL--(BUSINESS WIRE)--Jun. 8, 2023-- Repair Therapeutics Inc. ("Repair" or the "Company") (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today announced that members of its senior management team will participate in a fireside chat at the Goldman Sachs 44<sup>th</sup> Annual Global Healthcare Conference on Wednesday, June 14, 2023 at 2:00 p.m. Pacific Time/ 5:00 p.m. Eastern Time in Dana Point, California.

A live webcast of the fireside chat can be accessed in the Investor section of the Company's website at <https://ir.reparerx.com/news-and-events/events>. A replay of the webcast will be archived on the Company's website for 90 days.

### About Repair Therapeutics, Inc.

Repair Therapeutics is a leading clinical-stage precision oncology company enabled by its proprietary synthetic lethality approach to the discovery and development of novel therapeutics. The Company utilizes its genome-wide, CRISPR-enabled SNIPRx® platform to systematically discover and develop highly targeted cancer therapies focused on genomic instability, including DNA damage repair. The Company's pipeline includes lunresertib (also known as RP-6306), a PKMYT1 inhibitor currently in Phase 1 clinical development; camonsertib (also known as RP-3500 or RG6526), a potential leading ATR inhibitor currently in Phase 1/2 clinical development and partnered with Roche; a preclinical Polθ inhibitor program; as well as several additional, undisclosed preclinical programs, including RP-1664. For more information, please visit [reparerx.com](https://reparerx.com).

SNIPRx® is a registered trademark of Repair Therapeutics Inc.

View source version on [businesswire.com](https://www.businesswire.com/news/home/20230608005101/en/): <https://www.businesswire.com/news/home/20230608005101/en/>

### Repair Contact:

Robin Garner  
Executive Director and Head of Investor Relations  
Repair Therapeutics Inc.  
[investor@reparerx.com](mailto:investor@reparerx.com)

### Investors:

Matthew DeYoung  
Argot Partners  
[repare@argotpartners.com](mailto:repare@argotpartners.com)

### Media:

David Rosen  
Argot Partners  
[david.rosen@argotpartners.com](mailto:david.rosen@argotpartners.com)  
212-600-1902

Source: Repair Therapeutics Inc.